



Joint Working Executive Summary

Published on www.bayer.co.uk

Project title	Hounslow Atrial Fibrillation (AF) Community Pathway Project
Project partners	Bayer plc Chelsea & Westminster NHS Foundation Trust
Project summary	<p>This project aims to increase the prevalence of AF diagnosis in the Hounslow CCG geography by way of a 'Community AF Pathway'</p> <p>There are two elements to the project.</p> <ul style="list-style-type: none">• The pathway will identify patients in the community who may be unaware that they have Atrial Fibrillation by proactive screening by individuals trained to identify Atrial Fibrillation and ensuring onward referral to an appropriate health care professional.• Improve the available patient information.
Expected benefits to patients, the NHS and Bayer	<p>Patients will benefit from, initially being identified with AF and appropriate referral to a healthcare professional, receiving improved information on the disease area and ways to manage their condition.</p> <p>NHS will benefit from increased education and training of staff and volunteers, increase in disease prevalence rates that can be managed to reduce risk of AF related stroke and co morbid outcomes.</p> <p>Bayer will benefit from more patients being identified as being suitable for anticoagulation in line with NICE guidance, including DOACs of which Bayer's rivaroxaban is one, and gain a deeper understanding of the NHS and its workings.</p>
Start date	September 2016

Date of Recertification: September 2020

Job bag number: PP-OTH-GB-0463